Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3948070 | Gynécologie Obstétrique & Fertilité | 2009 | 5 Pages |
Abstract
A descriptive analysis of available data on reported cases of uterine carcinosarcomas associated with tamoxifen therapy is undertaken. The role of aromatase inhibitors as alternative to tamoxifen therapy in the adjuvant setting of breast cancer is discussed. The eventual implications of the presumed association of uterine carcinosarcoma and tamoxifen therapy on the choice of the therapeutic agent in the adjuvant setting of hormone-sensitive breast cancer are discussed.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
F. Leung, J.-J. Terzibachian, A. Govyadovskiy, A. Bourtembourg, R. Maillet, D. Riethmuller,